Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma.
Chinen Y, Tanba K, Takagi R, Uchiyama H, Uoshima N, Shimura K, Fuchida SI, Kiyota M, Nakao M, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Wada K, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M, Yokota I, Kuroda J; Kyoto Clinical Hematology Study Group investigators.
Chinen Y, et al. Among authors: tanba k.
Leuk Lymphoma. 2020 Dec;61(14):3378-3386. doi: 10.1080/10428194.2020.1811862. Epub 2020 Aug 27.
Leuk Lymphoma. 2020.
PMID: 32852234